Roivant Sciences Ltd (ROIV)
Roivant Sciences Ltd. (ROIV) Discusses FDA Approval of LISRAYA as First Oral Targeted Therapy for Dermatomyositis Transcript
Roivant Sciences Ltd. (ROIV) Discusses FDA Approval of LISRAYA as First Oral Targeted Therapy for Dermatomyositis Transcript
Roivant Sciences Wins FDA Approval for LISRAYA in Dermatomyositis, Launches Immediately
Roivant Sciences NASDAQ: ROIV said the U.S. Food and Drug Administration has approved LISRAYA, its once-daily oral therapy for adults with dermatomyositis, and that the drug has already entered commercial launch.
Roivant Sciences: The Balance Sheet Has Become A Strategic Weapon
Roivant Sciences is transitioning from an asset-monetization platform to a commercial-stage biopharma, supported by a strong cash position and imminent product launches. ROIV's $4.7 billion pro forma liquidity eliminates near-term dilution risk, enabling commercialization of brepocitinib and continued pipeline investment without adverse equity market reliance. Brepocitinib's FDA Priority Review for dermatomyositis, with potential approval by September 2026, anchors near-term upside, while label expansions target a >280,000 patient opportunity.
Roivant Sciences Q1 Earnings Call Highlights
Roivant Sciences NASDAQ: ROIV said it expects a busy second half of 2026, with a potential launch of brepocitinib in dermatomyositis, several clinical readouts and additional regulatory discussions across its pipeline.
Roivant Sciences Ltd. (ROIV) Q1 2026 Earnings Call Transcript
Roivant Sciences Ltd. (ROIV) Q1 2026 Earnings Call Transcript
Roivant Sciences Ltd. (ROIV) Reports Q1 Loss, Misses Revenue Estimates
Roivant Sciences Ltd. (ROIV) came out with a quarterly loss of $0.33 per share in line with the Zacks Consensus Estimate.
Roivant Sciences Ltd. (ROIV) Presents at Bernstein 42nd Annual Strategic Decisions Conference Transcript
Roivant Sciences Ltd. (ROIV) Presents at Bernstein 42nd Annual Strategic Decisions Conference Transcript
Roivant Sciences Ltd. (ROIV) Q4 2025 Earnings Call Transcript
Roivant Sciences Ltd. (ROIV) Q4 2025 Earnings Call Transcript
Roivant Sciences Ltd. (ROIV) Reports Q4 Loss, Misses Revenue Estimates
Roivant Sciences Ltd. (ROIV) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.26.
Montes Archimedes Acquisition (ROIV) Upgraded to Buy: Here's Why
Montes Archimedes Acquisition (ROIV) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Roivant Sciences Ltd. (ROIV) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Roivant Sciences Ltd. (ROIV) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Roivant Sciences Ltd. (ROIV) Discusses Brepocitinib Program Expansion and Phase III Batoclimab Data Update Transcript
Roivant Sciences Ltd. (ROIV) Discusses Brepocitinib Program Expansion and Phase III Batoclimab Data Update Transcript
